Sachin Jain Reiterates Buy on Improved Risk-Reward and Late-Stage Pipeline Strength, Keeps 140 CHF Price Target Unchanged

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on Novartis AG, with a price target of CHF140.00.

Sachin Jain has given his Buy rating due to a combination of factors, including an improved risk‑reward profile and a robust late‑stage pipeline heading into the next 6–12 months. The recent share price pullback of roughly 15% from the highs, combined with unchanged upside to his 140 CHF price target, enhances the attractiveness of the valuation relative to the company’s pipeline optionality.

He highlights multiple Phase III assets—such as remibrutinib in multiple sclerosis and hidradenitis suppurativa, del-desiran in DM1, del-brax in congenital Duchenne, and pelacarsen in cardiovascular disease—as key catalysts that can offset looming loss‑of‑exclusivity pressures. Jain believes that success in even a subset of these programs could drive material peak sales and re-rate the stock, while the downside from potential pipeline failures is already partly reflected in consensus, supporting his decision to maintain a Buy with a 140 CHF price objective (unchanged).

Jain covers the Healthcare sector, focusing on stocks such as AstraZeneca, Sanofi, and Novartis. According to TipRanks, Jain has an average return of 1.9% and a 50.63% success rate on recommended stocks.

In another report released on May 8, Kepler Capital also maintained a Buy rating on the stock with a CHF135.00 price target.